Abstract 460P
Background
Cancer diagnosis and treatment can give rise to psychological challenges for patients. Amidst the adversity, there exists the potential for post-traumatic growth (PTG), a phenomenon characterized by positive psychological changes and personal development following traumatic experiences. Group-based interventions have emerged as a promising avenue for fostering PTG among individuals with cancer. This systematic review aims to assess the group-based interventions designed to facilitate PTG in cancer patients.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used were group-based intervention, group therapy, PTG, positive psychological change, and cancer. Publications were limited to English manuscripts published in the last 10 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review encompassed a selection of 12 studies, with 970 individuals aged above 18 years. The sampled patients displayed wide cancer types, including breast, gynaecologic, hematologic, head and neck, gastrointestinal, urological, and lymphoma. Group therapies in this review were mindfulness-based psychotherapy, cognitive behavioural stress management, acceptance and commitment therapy, supportive and positive group therapy, art and relaxation response resiliency mind-body program, varied from 5-12 sessions. The primary assessment tool is Post-Traumatic Growth Inventory (PTGI). The findings suggest that group interventions contribute to the personal strength, positive affect, and sense of meaning in cancer-related trauma. While positive trends were observed, the magnitude of PTG outcomes varied, likely influenced by duration, composition, and participant readiness for growth.
Conclusions
To conclude, this systematic review assesses the potential of group-based interventions as resource in promoting PTG among cancer patients. Nevertheless, the variations in outcomes across studies emphasize the need for interventions, accounting for individual differences. This review contributes to our understanding of the relationship between group-based interventions and PTG among cancer patients, paving the way for further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D. G. William.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract